<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574024</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2019001677</org_study_id>
    <nct_id>NCT04574024</nct_id>
  </id_info>
  <brief_title>HFP (High-Fiber Supplement) in MS (Multiple Sclerosis)</brief_title>
  <official_title>Effect of High-fiber Supplement in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suhayl Dhib-Jalbut, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been suggested that dysbiosis of gut commensal bacteria increases the risk of&#xD;
      autoimmune diseases including MS. However, there is no viable intervention available to&#xD;
      correct dysbiosis. Since high-fiber supplement can promote the growth of healthy bacteria in&#xD;
      the gut, the investigators propose to examine the effect of specially designed high-fiber&#xD;
      supplement on the growth of short-chain fatty acid-producing gut bacteria and development of&#xD;
      regulatory immune cells.&#xD;
&#xD;
      Although dysbiosis is an alteration of microbial composition, enteric bacteria involved in&#xD;
      gut dysbiosis of MS are different in ethnic groups due to difference in genetics, diet, and&#xD;
      environmental exposures. Therefore, it is important to determine the intestinal bacterial&#xD;
      composition involved in the MS dysbiosis in each ethnicity and geographical location.&#xD;
      Additionally, it is necessary to find a non-invasive biomarker for gut dysbiosis-mediated CNS&#xD;
      autoimmunity in MS. Since the investigators found that fecal Lipocalin 2 (Lcn-2) is a&#xD;
      biomarker of gut dysbiosis-mediated CNS autoimmunity in MS animal models, the investigators&#xD;
      will examine the association of fecal Lcn-2 levels with disease activation in MS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">November 16, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>High-fiber supplement-treatment and non-treatment</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of high-fiber supplement (HFS) on (1) composition of gut microbiota and (2)production of short-chain fatty acids (SCFAs) and Foxp3 regulatory T cells (Tregs).</measure>
    <time_frame>Change from baseline to day183</time_frame>
    <description>(1) The fecal sample will be collected from MS patients with/without high-fiber supplement (HFS) and composition of gut microbiota will be examined. (2) The blood cells will be isolated from MS patients with/without HFS-treatment and production of SCFAs such as acetate, propionate, and butyrate, and development of Foxp3 Tregs will be examined.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Examine fecal Lcn-2 levels before/after MS relapse</measure>
    <time_frame>From date of randomization until the date of first documented progression, assessed up to 36 months</time_frame>
    <description>Fecal Lcn-2 levels will be examined in MS patients with remission and relapse</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cohort A: Treatment with NBT-NM108�</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive NBT-NM108 at 60 g/day for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B: Non-treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will not receive NBT-NM108.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NBT-NM108 (60 g/day)</intervention_name>
    <description>Patients will receive NBT-NM108 at 60 g/day.</description>
    <arm_group_label>Cohort A: Treatment with NBT-NM108�</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NBT-NM108 (0 g/day)</intervention_name>
    <description>Patients will receive NBT-NM108 at 0 g/day.</description>
    <arm_group_label>Cohort B: Non-treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with first demyelinating event who meet the McDonald criteria for definite MS&#xD;
             or established relapsing remitting MS patients.&#xD;
&#xD;
          2. We will recruit Caucasian due to reports suggesting higher incidence of MS in&#xD;
             Caucasian. Also, western diet which is common among Caucasian can promote MS.&#xD;
&#xD;
          3. MS patients treated with either Glatiramer acetate or Fingolimod for at least 6 months&#xD;
             prior to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Primary or secondary progressive MS.&#xD;
&#xD;
          2. Patients with autoimmune comorbidities.&#xD;
&#xD;
          3. Having received prior chemotherapy.&#xD;
&#xD;
          4. Having received Dimethylfumarate (DMF).&#xD;
&#xD;
          5. Pregnant women.&#xD;
&#xD;
          6. Cognitively impaired.&#xD;
&#xD;
          7. Antibiotic use within last 6 months.&#xD;
&#xD;
          8. Probiotic use within 2 months.&#xD;
&#xD;
          9. Self-reported allergy or intolerance to any ingredients in the fiber supplement&#xD;
&#xD;
         10. Self-reported or diagnosed gastrointestinal symptoms, disorders or adenomas&#xD;
&#xD;
         11. Active or history of malignant tumors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suhayl Dhib-Jalbut, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers-RWJMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Suhayl Dhib-Jalbut, MD</investigator_full_name>
    <investigator_title>Professor of Department of Neurology</investigator_title>
  </responsible_party>
  <keyword>High-fiber supplement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

